ORKA-002

Phase 2Small molecule

OOruka Therapeutics, Inc.

ORKA-002 is one of 12 small molecule programs targeting Hidradenitis Suppurativa (HS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hidradenitis Suppurativa (HS)Recruiting

Plaque PsoriasisActive, not recruiting

Hidradenitis Suppurativa (HS)Phase 2

Recruiting

Plaque PsoriasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Plaque Psoriasis

#DrugCompanyPhaseTrials

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

5 2

Envudeucitinib

AAlumis Inc

Phase 3

3 3

ESK-001

AAlumis Inc

Phase 2

3 4

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1 5

ORKA-001

OOruka Therapeutics, Inc.

Phase 2

3 6

ZP9830

Zealand Pharma

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Active, not recruiting

Plaque Psoriasis

NCT07474792

Q3 2029

Phase 2Recruiting

Hidradenitis Suppurativa (HS)

NCT07783542

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa (HS)1 trial

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

Recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07783542·200 enrolled

Plaque Psoriasis1 trial

A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07474792·160 enrolled

Unspecified1 trial

Phase 1, First-in-human, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Healthy Participants

Completed·OOruka Therapeutics, Inc.·Phase 1·NCT06944379·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ORKA-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ORKA-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ORKA-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oruka Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOruka Therapeutics, Inc.

ORKA-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2029

Trials by Indication[1]

Hidradenitis Suppurativa (HS)1 trial

Plaque Psoriasis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News